Dupilumab Demonstrates Superior 2-Year Drug Survival in Atopic Dermatitis Treatment Landscape
Key Insights
Dupilumab showed the highest 2-year drug survival rates among targeted atopic dermatitis (search) therapies, with 77.3% survival in treatment-naïve patients and 68.1% in previously treated patients.
JAK (search) inhibitors demonstrated lower persistence rates, with drug discontinuation primarily due to insufficient effectiveness (20.6%) and adverse events (13.7%).
The introduction of new targeted therapies doubled the risk of dupilumab discontinuation, indicating that treatment availability significantly influences drug survival outcomes.
A comprehensive analysis of 1,583 treatment episodes reveals that dupilumab maintains the highest drug survival rates among targeted atopic dermatitis (search) therapies, while the availability of alternative treatments significantly impacts treatment persistence patterns.
Dupilumab Leads in Long-Term Treatment Persistence
The multi-center BioDay registry study, led by Lian F. van der Gang from University Medical Center Utrecht, evaluated 2-year drug survival rates across five targeted atopic dermatitis (search) medications between January 2021 and October 2024. The analysis included 865 dupilumab, 227 tralokinumab, 144 abrocitinib, 106 baricitinib, and 241 upadacitinib treatment episodes.
In biologic- and JAK (search) inhibitor-naïve patients, dupilumab demonstrated superior persistence with 1- and 2-year survival rates of 84.9% and 77.3%, respectively. In comparison, JAK inhibitors showed notably lower persistence: abrocitinib achieved 60.2% and 27.1%, baricitinib 46.7% and 42.8%, and upadacitinib 72.6% and 63.5% at 1 and 2 years. Tralokinumab, the other IL-13 targeting biologic, showed 72.5% and 47.6% survival rates.
Treatment Experience Impacts Drug Survival
The study revealed that prior exposure to biologics or JAK (search) inhibitors significantly reduced drug survival across all medications. Among experienced patients, dupilumab maintained the highest persistence with 82.9% and 68.1% survival at 1 and 2 years, while other treatments showed markedly lower rates. Abrocitinib dropped to 53.7% and 27.8%, baricitinib to 29.6% and 22.4%, and upadacitinib to 61.3% and 49.4%.
Treatment discontinuation occurred most frequently due to insufficient drug effectiveness (20.6%), followed by adverse events (13.7%). Among patients discontinuing for efficacy reasons, 95.7% had an Eczema Area and Severity Index (EASI) score exceeding 7 and/or a Numeric Rating Scale (NRS) score for pruritus over 4.
Market Competition Affects Treatment Persistence
A secondary analysis examining dupilumab treatment episodes from 2017-2024 revealed that the availability of alternative targeted drugs significantly impacted treatment persistence. The introduction of new therapeutic options was associated with a twofold higher risk of dupilumab discontinuation (HR 2.0, 95% CI 1.4–2.5; P < .0001).
"This study highlights that the absence of alternative targeted therapies results in significantly longer drug survival, indicating that treatment availability influences drug survival outcomes," the investigators concluded.
Tralokinumab Provides Option After Dupilumab Failure
Complementary real-world data from NYU Langone Health demonstrated that tralokinumab offers meaningful clinical benefit for patients who fail dupilumab therapy. In a retrospective review of 49 patients, 51% of prior dupilumab users experienced clinical improvement on tralokinumab based on objective scores or patient-reported benefit.
The study showed significant reductions in disease burden within three months of tralokinumab initiation. Mean body surface area involvement decreased from 20.5% to 11.4%, while peak pruritus numeric rating scale scores fell from 6.2 to 4.2. Additionally, one-third of patients reduced their use of topical therapies and nearly half reported fewer disease flares.
Clinical Implications for Treatment Sequencing
The median dupilumab exposure before switching to tralokinumab was 333 days, indicating substantial trial periods before considering patients as nonresponders. For patients who discontinued dupilumab due to side effects, transition to tralokinumab was associated with resolution of conjunctivitis or head and neck dermatitis in some cases.
These findings suggest that drug survival analysis serves as an important indirect metric for treatment effectiveness and tolerability, reflecting both clinical outcomes and decision-making patterns among clinicians and patients. The data support tralokinumab as a viable therapeutic option for patients with inadequate response or intolerance to dupilumab, offering an alternative strategy through selective interleukin-13 (search) blockade within the same Th2 pathway.